Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Virologic Outcomes With Lenacapavir in People With Human Immunodeficiency Virus: A Multicenter Real-World Study.
Journal: Open forum infectious diseases
Published: February 10, 2026
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 28, 2025
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 28, 2025
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study.
Journal: Open forum infectious diseases
Published: August 05, 2025
Letter: Navigating HIV PCR Results in the Era of Long-Acting Injectable Pre-Exposure Prophylaxis.
Journal: AIDS patient care and STDs
Published: May 13, 2025
Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis.
Journal: AIDS (London, England)
Published: July 07, 2023
Cryptococcal Meningitis in an Immunocompetent Patient with a Ventriculo-Pleural Shunt.
Journal: Case reports in infectious diseases
Published: November 10, 2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Journal: The lancet. HIV
Published: January 03, 2019
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Journal: The lancet. HIV
Published: January 17, 2018
Chronic central serous chorioretinopathy responsive to rifampin.
Journal: Retinal cases & brief reports
Published: January 01, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026